Do analysts recommend KYNB or ADXN?

Kyntra Bio presently has a consensus price target of $32.50, indicating a potential upside of 349.21%. Given Kyntra Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Kyntra Bio is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend ATNM or ADXN?

Actinium Pharmaceuticals currently has a consensus target price of $5.00, indicating a potential upside of 448.25%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ATNM or ADXN more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat Addex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Addex Therapeutics N/A -134.76% -106.00%

Do analysts rate ADXN or TAOX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ADXN or TAOX more profitable?

Addex Therapeutics' return on equity of -134.76% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Addex Therapeutics N/A -134.76% -106.00% Synaptogenix N/A -163.40% -133.47%

Do analysts rate ADXN or BTAI?

BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 1,148.58%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate GRDX or ADXN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRDX or ADXN more profitable?

Entero Therapeutics' return on equity of -49.81% beat Addex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -49.81% -11.02% Addex Therapeutics N/A -134.76% -106.00%

Addex Therapeutics (ADXN) Competitors

$5.78 +0.19 (+3.30%)

As of 12:38 PM Eastern

Compare

ADXN vs. KYNB, ATNM, TAOX, BTAI, and GRDX

Should you buy Addex Therapeutics stock or one of its competitors? MarketBeat compares Addex Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Addex Therapeutics include Kyntra Bio (KYNB), Actinium Pharmaceuticals (ATNM), Synaptogenix (TAOX), BioXcel Therapeutics (BTAI), and Entero Therapeutics (GRDX). These companies are all part of the "pharmaceutical products" industry.

How does Addex Therapeutics compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Kyntra Bio has a net margin of 2,199.13% compared to Addex Therapeutics' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-36.71%
Addex Therapeutics	N/A	-134.76%	-106.00%

Kyntra Bio has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market.

Kyntra Bio has higher revenue and earnings than Addex Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.55	$183.45M	$40.46	0.18
Addex Therapeutics	$210K	33.88	-$8.12M	-$5.94	N/A

Kyntra Bio presently has a consensus price target of $32.50, indicating a potential upside of 349.21%. Given Kyntra Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Kyntra Bio is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Kyntra Bio's average media sentiment score of 0.00 equaled Addex Therapeutics'average media sentiment score.

Company	Overall Sentiment
Kyntra Bio	Neutral
Addex Therapeutics	Neutral

Summary

Kyntra Bio beats Addex Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Addex Therapeutics compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Addex Therapeutics has higher revenue and earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	317.93	-$48.82M	-$0.75	N/A
Addex Therapeutics	$210K	33.88	-$8.12M	-$5.94	N/A

Actinium Pharmaceuticals currently has a consensus target price of $5.00, indicating a potential upside of 448.25%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Actinium Pharmaceuticals' return on equity of -100.85% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Addex Therapeutics	N/A	-134.76%	-106.00%

Actinium Pharmaceuticals has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market.

In the previous week, Actinium Pharmaceuticals' average media sentiment score of 0.00 equaled Addex Therapeutics'average media sentiment score.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
Addex Therapeutics	Neutral

Summary

Actinium Pharmaceuticals beats Addex Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Addex Therapeutics compare to Synaptogenix?

Addex Therapeutics (NASDAQ:ADXN) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Addex Therapeutics' return on equity of -134.76% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-134.76%	-106.00%
Synaptogenix	N/A	-163.40%	-133.47%

Addex Therapeutics has higher earnings, but lower revenue than Synaptogenix. Addex Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	33.88	-$8.12M	-$5.94	N/A
Synaptogenix	$300K	92.13	-$28.74M	-$13.28	N/A

Addex Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

In the previous week, Addex Therapeutics' average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score.

Company	Overall Sentiment
Addex Therapeutics	Neutral
Synaptogenix	Neutral

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Addex Therapeutics beats Synaptogenix on 7 of the 10 factors compared between the two stocks.

How does Addex Therapeutics compare to BioXcel Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Addex Therapeutics has higher earnings, but lower revenue than BioXcel Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	33.88	-$8.12M	-$5.94	N/A
BioXcel Therapeutics	$640K	42.51	-$69.90M	-$5.75	N/A

Addex Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-134.76%	-106.00%
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%

16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 1,148.58%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Addex Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

In the previous week, Addex Therapeutics' average media sentiment score of 0.00 equaled BioXcel Therapeutics'average media sentiment score.

Company	Overall Sentiment
Addex Therapeutics	Neutral
BioXcel Therapeutics	Neutral

Summary

BioXcel Therapeutics beats Addex Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Addex Therapeutics compare to Entero Therapeutics?

Entero Therapeutics (NASDAQ:GRDX) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Entero Therapeutics has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled Addex Therapeutics'average media sentiment score.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Addex Therapeutics	Neutral

Entero Therapeutics has higher earnings, but lower revenue than Addex Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	589.08	-$6.39M	-$1.88	N/A
Addex Therapeutics	$210K	33.88	-$8.12M	-$5.94	N/A

Entero Therapeutics' return on equity of -49.81% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
Addex Therapeutics	N/A	-134.76%	-106.00%

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Entero Therapeutics beats Addex Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Addex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADXN vs. The Competition

Export

Metric	Addex Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.12M	$3.08B	$6.80B	$12.44B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-0.97	20.11	27.00	24.19
Price / Sales	33.88	344.93	518.66	94.29
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	1.24	4.27	10.68	6.26
Net Income	-$8.12M	$65.94M	$3.59B	$331.52M
7 Day Performance	-4.06%	-1.50%	-0.19%	-1.19%
1 Month Performance	-6.69%	0.12%	1.93%	-1.35%
1 Year Performance	-28.26%	17.43%	25.24%	18.74%

Addex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADXN Addex Therapeutics	0.1923 of 5 stars	$5.79 +3.3%	N/A	-24.8%	$7.12M	$210K	N/A	30	Gap Up
KYNB Kyntra Bio	3.0086 of 5 stars	$7.21 -1.5%	$32.50 +350.8%	N/A	$29.20M	$6.44M	0.18	570
ATNM Actinium Pharmaceuticals	1.8664 of 5 stars	$0.92 +2.8%	$5.00 +443.5%	-48.4%	$28.86M	$90K	N/A	30
TAOX Synaptogenix	0.2582 of 5 stars	$3.83 +2.4%	N/A	N/A	$28.61M	$300K	N/A	4
BTAI BioXcel Therapeutics	2.1919 of 5 stars	$0.92 -10.5%	$11.00 +1,093.7%	-53.8%	$28.46M	$640K	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADXN) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Addex Therapeutics (ADXN) Competitors

ADXN vs. KYNB, ATNM, TAOX, BTAI, and GRDX

How does Addex Therapeutics compare to Kyntra Bio?

Summary

How does Addex Therapeutics compare to Actinium Pharmaceuticals?

Summary

How does Addex Therapeutics compare to Synaptogenix?

Summary

How does Addex Therapeutics compare to BioXcel Therapeutics?

Summary

How does Addex Therapeutics compare to Entero Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN vs. The Competition

Addex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Addex Therapeutics (ADXN) Competitors

ADXN vs. KYNB, ATNM, TAOX, BTAI, and GRDX

How does Addex Therapeutics compare to Kyntra Bio?

Is KYNB or ADXN more profitable?

Which has more volatility and risk, KYNB or ADXN?

Which has preferable valuation and earnings, KYNB or ADXN?

Do analysts recommend KYNB or ADXN?

Do institutionals and insiders believe in KYNB or ADXN?

Does the media prefer KYNB or ADXN?

Summary

How does Addex Therapeutics compare to Actinium Pharmaceuticals?

Do institutionals & insiders believe in ATNM or ADXN?

Which has better earnings & valuation, ATNM or ADXN?

Do analysts recommend ATNM or ADXN?

Is ATNM or ADXN more profitable?

Which has more volatility & risk, ATNM or ADXN?

Does the media prefer ATNM or ADXN?

Summary

How does Addex Therapeutics compare to Synaptogenix?

Is ADXN or TAOX more profitable?

Which has preferable earnings & valuation, ADXN or TAOX?

Which has more risk & volatility, ADXN or TAOX?

Does the media favor ADXN or TAOX?

Do insiders & institutionals have more ownership in ADXN or TAOX?

Do analysts rate ADXN or TAOX?

Summary

How does Addex Therapeutics compare to BioXcel Therapeutics?

Which has stronger earnings & valuation, ADXN or BTAI?

Is ADXN or BTAI more profitable?

Do institutionals & insiders hold more shares of ADXN or BTAI?

Do analysts rate ADXN or BTAI?

Which has more risk and volatility, ADXN or BTAI?

Does the media refer more to ADXN or BTAI?

Summary

How does Addex Therapeutics compare to Entero Therapeutics?

Which has more risk & volatility, GRDX or ADXN?

Does the media favor GRDX or ADXN?

Which has stronger valuation and earnings, GRDX or ADXN?

Is GRDX or ADXN more profitable?

Do institutionals and insiders believe in GRDX or ADXN?

Do analysts rate GRDX or ADXN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN vs. The Competition

Addex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools